Deguchi K, Koguchi M, Suzuki Y, Tanaka S, Fukayama S, Ishihara R, Oda S
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1996 Mar;49(3):279-88.
We investigated antibacterial activities of combination uses of isepamicin (ISP) and beta-lactams in vitro against Klebsiella pneumoniae and Enterobacter cloacae, and the following conclusions were obtained. 1. ISP+cefazolin, ISP+cefotiam and ISP+flomoxef against K. pneumoniae and ISP+piperacillin, ISP+ceftazidime, ISP+aztreonam, ISP+imipenem and ISP+panipenem against E. cloacae showed strong combined effects. 2. The minimum inhibitory concentrations (MICs) of these combinations were low due to the dependence of ISP concentrations. Strong antibacterial activities were observed at sub-MIC levels of ISP. These combined effects were stronger than those against Staphylococcus aureus described in the first report at sub-MIC levels of ISP. 1/4 MIC approximately 1/8 MIC of ISP showed enhanced activities of beta-lactams. Similarly strong combined effects were observed against both beta-lactam-sensitive and -resistant strains.
我们研究了异帕米星(ISP)与β-内酰胺类药物联合使用对肺炎克雷伯菌和阴沟肠杆菌的体外抗菌活性,得出以下结论。1. ISP+头孢唑林、ISP+头孢替安和ISP+氟氧头孢对肺炎克雷伯菌,以及ISP+哌拉西林、ISP+头孢他啶、ISP+氨曲南、ISP+亚胺培南和ISP+帕尼培南对阴沟肠杆菌均显示出强大的联合效应。2. 由于ISP浓度的依赖性,这些联合用药的最低抑菌浓度(MIC)较低。在ISP的亚MIC水平观察到强大的抗菌活性。这些联合效应强于首次报告中在ISP亚MIC水平对金黄色葡萄球菌的联合效应。ISP的1/4 MIC至约1/8 MIC显示出β-内酰胺类药物活性增强。对β-内酰胺类敏感和耐药菌株均观察到类似的强大联合效应。